A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes
Johnston, Curtis K., Rena J. Eudy-Byrne, Ahmed Elmokadem, Valerie Nock, Jan Marquard, Nima Soleymanlou, Matthew M. Riggs, and Karl-Heinz Liesenfeld. 2021. Pharmaceutics 13 (4): 485. https://doi.org/10.3390/pharmaceutics13040485